A Novel Device for Suprachoroidal Drug Delivery to Retina: Evaluation in Nonhuman Primates
Translational Vision Science & Technology · 2023
DOI: 10.1167/tvst.12.6.3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Vision Science & Technology, 2023. Verfasst von Ygal Rotenstreich und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel. Hauptthemen laut MEDLINE: Choroid, Retina. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
Evaluation of distribution and tolerance of suprachoroidal injection of indocyanine green (ICG) in nonhuman primates (NHPs) using a novel suprachoroidal (SC) delivery technology.
Methods
Three live and three euthanized African green monkeys were injected with 150 or 200 µL ICG/eye into the SC space of both eyes, 2.5 mm posterior to the limbus in the inferior quadrant, utilizing a novel SC injector. Eyes were analyzed by imaging of scleral flatmounts. Live animals were observed for 24 hours for general health. Ophthalmic evaluation included slit-lamp biomicroscopy, tonometry, fundus imaging, confocal laser ophthalmoscopy, and spectral-domain optical coherence tomography (SD-OCT) before and at 10 minutes and 1, 3, and 24 hours post-injection.
Results
SC dosing was successfully performed in all eyes. Infrared fundus imaging demonstrated ICG distribution throughout the posterior segment, reaching the macula within 24 hours post-injection. No inflammation, intravitreal penetration, SC blebs, retinal detachment, or hemorrhages were detected. No significant changes were observed in retinal thickness by SD-OCT (P = 0.267, ANOVA). A mild, statistically insignificant elevation in intraocular pressure was observed within 10 minutes post-injection (mean ± standard error: 7.28 ± 5.09 mmHg; P = 0.061) and was spontaneously resolved within the first hour after dosing.
Conclusions
Suprachoroidal injection of 150 to 200 µL ICG dye was successfully performed and well tolerated in NHP eyes, with rapid distribution into the macular region and throughout the posterior pole. Translational Relevance: This novel SC drug delivery system may potentially provide safe and effective delivery of therapeutics to the posterior pole region in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel.
- The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
- TELEM Rubin Excellence in Biomedical Research Program, Sheba Medical Center, Tel Hashomer, Israel.
- Virscio, Inc., New Haven, CT, USA.
- Everads Therapy Ltd., Tel Aviv, Israel.
Zitieren
APA
Rotenstreich, Y., Sher, I., Lawrence, M., Mangelus, M., Ingerman, A., & Barak, Y. (2023). A Novel Device for Suprachoroidal Drug Delivery to Retina: Evaluation in Nonhuman Primates. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.12.6.3
Vancouver
Rotenstreich Y, Sher I, Lawrence M, Mangelus M, Ingerman A, Barak Y. A Novel Device for Suprachoroidal Drug Delivery to Retina: Evaluation in Nonhuman Primates. Translational Vision Science & Technology. 2023. doi:10.1167/tvst.12.6.3
BibTeX
@article{Rotenstreich2023,
author = {Rotenstreich, Ygal and Sher, Ifat and Lawrence, Matthew and Mangelus, Miriam and Ingerman, Avner and Barak, Yoreh},
title = {A Novel Device for Suprachoroidal Drug Delivery to Retina: Evaluation in Nonhuman Primates},
journal = {Translational Vision Science & Technology},
year = {2023},
doi = {10.1167/tvst.12.6.3}
}
EUVIMED